Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Report found business relationships between telehealth and pharma companies may indirectly lead patients toward certain branded drugs ...

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

The obstructive sleep apnea (OSA) market is being propelled by the rapid evolution of early detection and diagnostic tools. Technologies like home sl ...

LLY, NFLX, and GE lead this week???s top research picks as strong demand, growth strategies, and sector tailwinds fuel ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

This week, Phil Oakley has analysed two shares, DexCom (US:DXCM) and Auto Trader (AUTO), which have decent earnings growth forecasts but rich valuations. It looks like both companies will need ...

LLY, NFLX, and GE lead today's top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and costs ...

This lawsuit may look like a business dispute on the surface. But underneath, it’s about something much more important: the right of patients to receive personalized, affordable care.

Pharmaceutical giant Cipla plans to enter India's weight management sector, while also bolstering its central nervous system ...

US pharma major Eli Lilly’s orforglipron is emerging as a promising oral glucagon-like peptide (GLP)-1 therapy, with upcoming clinical milestones in obesity and diabetes set to shape its market ...